Carbapenemase-Producing vs. AmpC-Producing Bacteria: Key Clinical Differences
Fundamental Mechanism Distinction
- Carbapenemase producers hydrolyze carbapenems and nearly all beta-lactams, while AmpC producers remain susceptible to carbapenems despite resistance to cephalosporins 1
- Carbapenemases (Classes A, B, and D) actively destroy carbapenems, rendering them ineffective 2, 1
Resistance Spectrum
Carbapenemase Producers
- Confer resistance to virtually all beta-lactams including carbapenems, broad-spectrum cephalosporins, penicillins, and beta-lactamase inhibitor combinations 2, 1
- Three main enzyme classes with distinct profiles:
AmpC Producers
- Critically, remain susceptible to carbapenems 4
- Can be chromosomal (cAmpC) in Enterobacter, Citrobacter, Serratia species or plasmid-mediated (pAmpC) in E. coli, Klebsiella, Proteus
Clinical Expression Patterns
Carbapenemase Producers
- Constitutively expressed resistance that is immediately apparent on susceptibility testing 2
- Require rapid molecular testing to identify specific carbapenemase family for optimal treatment selection 2
AmpC Producers
- Inducible expression (chromosomal AmpC): Strains initially appear susceptible to third-generation cephalosporins but develop resistance during therapy through mutation
- This inducibility creates a major pitfall: Enterobacter species may test susceptible to ceftriaxone initially but develop resistance mid-treatment, causing clinical failure 4
Treatment Implications
Carbapenemase Producers
- Treatment depends entirely on enzyme class 2, 3
- KPC producers: Ceftazidime/avibactam or meropenem/vaborbactam as first-line (STRONG recommendation) 3
- MBL producers: Ceftazidime/avibactam PLUS aztreonam or cefiderocol (STRONG recommendation) 3
- OXA-48 producers: Ceftazidime/avibactam (CONDITIONAL recommendation) 3
AmpC Producers
- Avoid third-generation cephalosporins in species with inducible AmpC (Enterobacter, Citrobacter, Serratia) even if initially susceptible 4
Epidemiological Context
Carbapenemase Producers
- Predominantly healthcare-associated infections 2
- Carbapenem resistance increased seven-fold since 2006 in Europe 2, 3
- Some countries report >50% carbapenem resistance in K. pneumoniae 2
Critical Pitfalls to Avoid
- Never use third-generation cephalosporins for serious infections caused by Enterobacter, Citrobacter, or Serratia species, even when susceptibility testing shows sensitivity 4
- Do not assume carbapenem resistance means carbapenemase production 2
- Recognize that 5-10% of cephalosporin-resistant K. pneumoniae produce plasmid-mediated AmpC rather than ESBL 4